Product Description
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tianjin Hemay Bio-Tech
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Behcet Syndrome|Psoriasis
Phase 2: Colitis, Ulcerative|Dermatitis, Atopic|Spondylitis, Ankylosing
Phase 1: Chronic Obstructive Pulmonary Disease|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06908642 |
HM005CO1S01 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2025-06-03 |
88% |
2025-12-11 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05486104 |
HM005UC2S01 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2025-12-30 |
12% |
2025-04-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05769946 |
HM005AD2S01 | P2 |
Completed |
Dermatitis, Atopic |
2024-01-24 |
69% |
2024-03-02 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06145893 |
HM005BD3S01 | P3 |
Recruiting |
Behcet Syndrome |
2026-05-30 |
27% |
2025-04-09 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
NCT05407246 |
HM005AS2S01 | P2 |
Completed |
Spondylitis, Ankylosing |
2023-08-18 |
55% |
2024-01-12 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT06376474 |
HM005PS1S06 | P1 |
Recruiting |
Psoriasis |
2025-12-10 |
50% |
2025-03-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05941247 |
HM005PS1S05 | P1 |
Completed |
Healthy Volunteers |
2023-08-08 |
69% |
2024-03-02 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20244741 |
CTR20244741 | P1 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20241162 |
CTR20241162 | P1 |
Active, not recruiting |
Psoriasis |
None |
2025-08-24 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20241161 |
CTR20241161 | P1 |
Recruiting |
Psoriasis |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20221214 |
CTR20221214 | P2 |
Completed |
Spondylitis, Ankylosing |
2023-06-26 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20222690 |
CTR20222690 | P2 |
Recruiting |
Dermatitis, Atopic |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20221945 |
CTR20221945 | P2 |
Recruiting |
Colitis, Ulcerative |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20210660 |
CTR20210660 | P3 |
Completed |
Psoriasis |
2023-07-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232593 |
CTR20232593 | P3 |
Recruiting |
Behcet Syndrome |
None |
2025-04-29 |
||
NCT06380153 |
HM005PS1S07 | P1 |
Completed |
Psoriasis |
2025-04-16 |
50% |
2025-12-05 |
Primary Completion Date|Primary Endpoints |
CTR20243397 |
CTR20243397 | P1 |
Completed |
Psoriasis |
2025-01-20 |
2025-08-24 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06610890 |
HM005PS1S08 | P1 |
Completed |
Psoriasis |
2025-01-20 |
50% |
2025-12-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20243188 |
CTR20243188 | P1 |
Completed |
Psoriasis |
2024-10-11 |
2025-07-19 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06610903 |
HM005PS1S09 | P1 |
Completed |
Psoriasis |
2024-09-30 |
75% |
2025-03-19 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|